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The aim was to investigate the effectiveness of glucocorticoid therapy in patients with COVID-19. A 33 
systematic search of the literature across 9 databases was conducted from inception until 15th March 34 
2020, following the PRISMA guidelines. Patients with a validated diagnosis of COVID-19 and using 35 
corticosteroids were included, considering all health outcomes. Four studies with 542 Chinese 36 
participants were included. Two studies reported negative findings regarding the use of corticosteroids 37 
in patients with COVID-19, i.e. corticosteroids had a detrimental impact on clinical outcomes; one 38 
study reported no significant association between the use of corticosteroids and clinical outcomes. One 39 
study, on the contrary, in 201 participants with different stages of pneumonia due to COVID-19, found 40 
that in more severe forms, the administration of methylprednisolone significantly reduced the risk of 41 
death by 62%. The literature to date does not fully support the routine use of corticosteroids in COVID-42 
19, but some findings suggest that methylprednisolone could lower mortality rate in more severe forms 43 
of the condition. 44 
1 Introduction 45 
Coronaviruses are ribonucleic acid viruses. Importantly, in humans the viruses may infect the 46 
respiratory, gastrointestinal, hepatic and central nervous systems [1]. Infection with four of the most 47 
common coronaviruses strains (HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1) usually 48 
lead to mild, self-limiting upper respiratory tract infections [2]. However, other coronaviruses, are 49 
associated with severe acute respiratory syndrome (SARS-CoV) and the Middle East respiratory 50 
syndrome (MERS-CoV).  51 
In March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a global 52 
pandemic. COVID-19 is caused by SARS-CoV-2, a variant of coronavirus. As of 10 April 2020, over 53 
1,500,000 confirmed cases have been diagnosed in more than 130 countries and areas, resulting in 54 
about 93,000  fatalities thus far [3]. Symptoms of infection are usually non-specific, and include fever, 55 
cough, and myalgia, with diarrhoea, with or without the subsequent development of dyspnea [4]. 56 
Severe cases that include respiratory distress, sepsis, and septic shock have been increasingly reported 57 
[5].  58 
During the SARS-CoV epidemic of 2003, therapeutic systemic corticosteroids were administered in 59 
patients who were infected and developed severe respiratory disease. In a meta-analysis of 60 
corticosteroid use in patients with SARS, only four studies provided conclusive data, all indicating 61 
higher mortality [6]. One recent systematic review and meta-analysis identified ten observational 62 
studies investigating the administration of corticosteroids in 6,458 patients affected by influenza [7]. 63 
The review identified increased mortality in patients who were given corticosteroids. Moreover, the 64 
length of stay in an intensive care unit was increased, as was the rate of secondary bacterial or fungal 65 
infection. Corticosteroids have been investigated also for respiratory syncytial virus (RSV) in clinical 66 
trials in children, with no conclusive evidence of benefit and are therefore not recommended [8].  67 
Two recent commentaries published in the Lancet between February and March 2020 reported that 68 
corticosteroids should not be used for the treatment of COVID-19 [9,10]. However, these assumptions 69 
are mainly based on the findings of the meta-analyses cited above, on disease caused by similar viruses, 70 
but not research on COVID-19 specifically.  71 
Therefore, the clinical, therapeutic, and side effects of systemic glucocorticoid therapy in COVID-19 72 
patients are currently unclear. Given this background, the present review investigates the effectiveness 73 
of glucocorticoid therapy in patients with COVID-19, by applying a systematic review of the literature 74 
   
  Corticosteroids in COVID-19 Pneumonia 
 
3 
currently available. The main objective is to investigate whether there is a clinical necessity, or 75 
therapeutic justification, for the use of systemic corticosteroids in patients with COVID-19. 76 
2 Methods 77 
This systematic review followed the MOOSE and PRISMA guidelines [11,12].  78 
2.1 Data sources and literature search strategy 79 
Two investigators (NV and JD) independently conducted a literature search using Embase, PubMed, 80 
Web of Science, CNKI, Medline, Cinahl, Toxline, SCOPUS. Specific research in Chinese database 81 
Wan-Fang of published and unpublished literature was conducted by one author LY and checked by 82 
another researcher (LZ).  The database search was run from database inception until 15th March 2020. 83 
All studies reporting information regarding the use of corticosteroids in COVID-19 were included. In 84 
PubMed, the following search strategy was used: “(COVID-19 OR Novel Coronavirus–Infected 85 
Pneumonia OR 2019 novel coronavirus OR 2019-nCoV OR SARS-CoV-2) AND (cortic* OR 86 
“glucocorticoids” OR “steroids” OR “corticosteroids” OR “hydrocortisone” OR “prednisone” OR 87 
“methylprednisolone” OR “dexamethasone” OR “prednisolone”). The strategy was then adapted for 88 
the other databases. Conference abstracts and reference lists of included articles were hand-searched 89 
to identify any potential additional relevant articles. Any inconsistencies were resolved by consensus 90 
with a third author (LS). 91 
2.2 Study selection 92 
Following the PICO framework [13], we included: participants who had a validated diagnosis of 93 
COVID-19, irrespective of stage or severity; intervention: use of corticosteroids (no a priori definition 94 
of dosage or route was made); comparison: patients affected by COVID-19 not taking corticosteroids; 95 
outcomes: all health outcomes were included, due to the anticipated scarcity of data. A priori, both 96 
intervention and observational data were considered. 97 
2.3 Data extraction 98 
Two independent investigators (NV and JD) extracted key data from the included articles in a 99 
standardized Excel database and a third independent investigator (LS) validated the data extraction. 100 
For each article, we extracted data regarding authors, year of publication, country, city or region in 101 
which the study was conducted, the period of observation, how the diagnosis of COVID-19 was 102 
obtained, the stage of  COVID-19 infection (asymptomatic forms, pneumonia, acute respiratory 103 
distress syndrome (ARDS), requiring intensive care unit, ICU; convalescent), sample size included, 104 
number of males and females, mean age and its standard deviation (or similar information such as 105 
median and range), the percentage of people treated with corticosteroids in the sample as a whole, and, 106 
if possible, the route of administration and type of corticosteroid considered. The dosage of 107 
corticosteroids used in these studies was mainly unavailable. 108 
2.4 Data synthesis and statistical analysis 109 
Data are reported descriptively according to the best evidence synthesis. When possible, numerical 110 
data, are reported. 111 
 112 
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3 Results 114 
3.1 Search results 115 
As shown in Figure 1, among 31 initially included studies (14 in English and 17 in Chinese), eight 116 
were reviewed as full-text and four finally included [14-17]. Two studies were excluded since they 117 
were commentaries [9,10], one excluded as it was a protocol [18] and one a letter to Editor [19]. 118 
3.2 Patients characteristics and main findings 119 
Table 1 shows the descriptive characteristics of the four included studies. Altogether, 542 Chinese 120 
participants, mainly males (=55.7%) of a mean age of 52 years (range: 34-68) were included. All the 121 
studies were conducted between the end of 2019 and February 2020. The diagnosis of COVID-19 was 122 
made in all the studies using reverse transcriptase-polymerase chain reaction on throat swab samples. 123 
Three among the four studies included pneumonia, at any stage, from mild to more complicated forms 124 
and one convalescent people.  125 
Table 2 summarizes the findings of the studies included. The percentage of patients taking 126 
corticosteroids ranged from 7.6 to 44.9% of the cohorts included. Two studies [14,15] reported negative 127 
findings regarding the use of corticosteroids in patients with COVID-19 since Wang et al [15] showed 128 
the group treated with corticosteroids experience a doubled risk of being admitted to an ICU; in Ling 129 
et al [14], the duration of viral RNA for oropharyngeal swabs and faeces was almost doubled in 130 
corticosteroids group than controls. Liu et al did not report any benefit of the use of intravenous 131 
methylprednisolone (30–80 mg/day) on clinical outcomes (i.e. short-term disease progression) in 137 132 
participants [17]. Finally, Wu et al carried out among 201 participants with different stages of 133 
pneumonia due to COVID-19, found that in more severe forms (i.e. in subjects having ARDS due to 134 
COVID-19), the administration of standard doses of methylprednisolone significantly reduced the risk 135 
of death by 62% [16]. 136 
4 Discussion 137 
In this systematic review including 542 Chinese patients, we have for the first time summarized the 138 
ultimate available literature regarding the use of corticosteroids in the treatment of a recent viral 139 
condition that is wide spreading on a global scale. Overall, two studies reported negative findings 140 
regarding these medications, one reported no significant association between corticosteroids and 141 
clinical outcomes and one concluded that methylprednisolone was associated with a significant 142 
reduction of mortality in patients with COVID-19 pneumonia developing ARDS.  143 
Since COVID-19 was first reported in December 2019, it has attracted global attention owing to its 144 
similarity to SARS-CoV and MERS-CoV in causing fatal respiratory disease, and its potential for 145 
causing large-scale human infection and economic disruption. When considering patients with SARS 146 
and MERS, the use of corticosteroids therapy is still debated [20,21]. Corticosteroids therapy was used 147 
in the treatment of severe SARS because early anecdotal experience supported it, and radiological 148 
findings and histologic features of critically ill patients with SARS were similar to those of patients 149 
with ARDS [22,23]. In March 2003, China summarized its experience in the management of SARS, 150 
and suggested that high-dose glucocorticoids should be used if patients had fever persisting for more 151 
than 3 days, or if radiologic findings were suggestive of persistent lung involvement or progressive 152 
deterioration [24]. One systematic review of studies on patients with SARS-CoV, including 29 studies 153 
documenting glucocorticoid use, found 25 studies that were inconclusive regarding the role of the 154 
adjunctive use of glucocorticoids to standard therapy, and 4 studies demonstrated that the use of 155 
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systemic glucocorticoids in SARS patients may cause possible harm [6]. Moreover, a prospective, 156 
randomized double-blinded, placebo-controlled trial compared early hydrocortisone treatment (before 157 
day 7 of the illness) with placebo, and found that early hydrocortisone therapy was associated with a 158 
higher subsequent plasma viral load [25].  159 
Glucocorticoid therapy was also used for critically ill patients with MERS. In one study, hypoxemic 160 
patients with MERS-CoV pneumonia who were not showing signs of improvement, were given 161 
glucocorticoid therapy [20]. However, the study reported that there was no difference in 90-days 162 
mortality, and these patients were associated with delayed MERS-CoV RNA clearance. This finding 163 
is somewhat confirmed in our systematic review on COVID-19, since one study reported that the 164 
duration of viral RNA for oropharyngeal swabs and faeces was almost doubled in corticosteroids group 165 
compared to controls [14]. 166 
Among those infected with COVID-19, some develop mild symptoms, however, a significant 167 
proportion progress to severe ARDS and thus require intensive care [26]. The use of corticosteroids in 168 
patients presenting with ARDS of different aetiologies remains controversial owing to mixed results 169 
in the existing literature, mainly derived from observational studies [27]. Globally, high-dose 170 
glucocorticoids is among the most frequently used adjuncts in ARDS (17.9%) [28]. Systemic 171 
corticosteroids have long been used among critically ill patients presenting with ARDS given their role 172 
in lowering the circulating levels of proinflammatory mediators [29,30]. Moreover, adequate and 173 
prolonged glucocorticoid supplementation have proved to mitigate the Critical Illness Related 174 
Corticosteroid Insufficiency (CIRCI) thus enhancing resolution of lung and systemic inflammation 175 
[31]. One systematic review conducted an analysis of individual patient data from randomized trials, 176 
and found that, compared with the placebo group, prolonged glucocorticoid treatment improved 177 
clinical outcomes [32]. A recent individual patient data meta-analysis combined four RCTs evaluating 178 
prolonged methylprednisolone therapy for ARDS, reported a significant reduction in mortality, with 179 
an increase in ventilator-free days (13 vs. 7, p<0.001) [33].  180 
Recent evidence suggests that a subset of patients with severe COVID-19 may have cytokine storm 181 
syndrome [34], which is a condition frequently related to lung involvement (including ARDS) [35] and 182 
multi-organ failure. In order to induce immunosuppression to antagonize virally driven 183 
hyperinflammation, treatments with tocilizumab (IL-6 receptor blockade) are ongoing in patients in 184 
which a hypercytokinemia laboratory pattern is identified. In these patients, a therapeutic role can also 185 
be hypothesized for corticosteroids [36]. 186 
Animal experiments may also provide evidence during the acute phase of severe disease for the use of 187 
glucocorticoids to (i) reduce inflammation, (ii) attenuate acute lung injury, and (iii) improve survival 188 
[32]. However, other studies have failed to provide convincing evidence to prove the efficacy of 189 
corticosteroids in decreasing the mortality of ARDS, thus suggesting that glucocorticoid therapy is not 190 
necessary in this condition, and may even aggravate the clinical course of the disease. Challenging 191 
analytic issues within these studies (including immortal time bias and indication bias from time-varying 192 
confounding) make these results inconclusive and larger specifically designed clinical trials are needed 193 
to clarify the favourable and unfavourable effects for corticosteroid therapy in ARDS patients. 194 
The present review has summarized the current evidence of corticosteroids on clinical outcomes in 195 
COVID-19 to inform clinicians and policymakers on the current state of the literature. Importantly, 196 
one study identified in this review in patients with ARDS owing to COVID-19 infection showed that 197 
methylprednisolone significantly decreased the risk of mortality. It should be noted that there is 198 
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currently one ongoing clinical trial that is directly addressing this research question and its results are 199 
eagerly awaited [18].  200 
The present review should be interpreted in light of its limitations. First, only four studies from China 201 
were included and heterogeneous data were reported. More research on this topic is needed before 202 
concrete recommendations can be made. Second, the type and dosage of corticosteroids varied between 203 
studies and, except in the case of Wu et al. [16], corticosteroids were considered as only class whilst 204 
they have different actions and properties. Third, the data are based only on retrospective findings and 205 
cohort studies are now urgently needed. Finally, existing data comes only from China and, 206 
consequently, it is not known if the genetic background of Chinese people may modify the results 207 
found in the present work and in which direction. 208 
5 Conclusions 209 
In conclusion, the literature so far available does not fully encourage the routine use of corticosteroids 210 
in COVID-19, but some findings suggest that methylprednisolone could lower mortality rate in more 211 
severe forms of this condition, such as in ARDS. Findings from future clinical trials, that are ongoing, 212 
are needed to better understand the role of corticosteroids in COVID-19. 213 
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Table 1. Descriptive characteristics of the studies included 
Author, 
year 
City/region Period of observation COVID diagnosis 
Stage of  
COVID 
Sample 
size 
Number 
of males 
Mean/median 
age 
(SD or range) 
Liu, 
2020 
Nine tertiary hospitals in 
Hubei province 
December 30, 2019 to  
January 24, 2020 
RT-PCR on Throat 
swab samples 
Pneumonia 137 61 
55 
(16) 
Wang, 
2020 
Zhongnan Hospital 
ofWuhan University 
January 1 to  
January 28, 2020 
RT-PCR on Throat 
swab samples 
Pneumonia 138 75 
56 
(42-68) 
Wu, 
2020 
Wuhan Jinyintan Hospital 
December 25, 2019 to  
January 26, 2020 
RT-PCR on Throat 
swab samples 
Pneumonia 201 128 
51 
(43-60) 
Ling, 
2020 
Shanghai Public Health 
Clinical Center 
January 20, 2020 to  
February 10, 2020 
RT-PCR on Throat 
swab samples 
Convalescent 66 38 
44 
(34-62) 
Abbreviations: COVID: coronavirus disease 2019; RT-PCR: Reverse transcriptase-polymerase chain reaction.    
  311 
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Table 2. Main findings of the studies included 
Author, year 
Percentage of people treated  
with corticosteroids 
Findings regarding corticosteroids 
Liu, 2020 29.2 
Intravenous methylprednisolone (30– 
80 mg/day) did not show significant benefits.   
Not numerical data were reported 
Wang, 2020 44.9 
Glucocorticoid therapy was associated with a greater risk of ICU 
admission:  26 (72.2) vs. 36 (35.3), p<0.001 
Wu, 2020 30.8 
Administration of methylprednisolone reduced the risk of death (hazard 
ratio, 0.38; 95%CI, 0.20-0.72; P = 0.003) in subjects having ARDS for 
COVID 19 
Ling, 2020 7.6 
The duration of viral RNA detection for oropharyngeal swabs and feces 
in the corticosteroid treatment group was longer than that in the non-
corticosteroid treatment group, which were 15 days vs. 8.0 days (P = 
0.013) and 20 days vs. 11 days (P <0.001). 
Abbreviations: ICU: intensive care unit; ARDS: Acute respiratory distress syndrome; COVID: coronavirus disease 2019. 
312 
  
Figure 1. PRISMA flow-chart 
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